No title
Background: To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents. Study design: This phase 3, open-label study was an extension of 3 phase 2 studies with participants aged 11–18 years randomize
